Dupilumab Does Not Cause Red Blood Cell Agglutination
Based on the FDA drug label and available evidence, dupilumab does not cause red blood cell agglutination. The FDA prescribing information for dupilumab makes no mention of agglutination as an adverse effect, and the extensive clinical trial data spanning up to 5 years shows no clinically meaningful changes in hematologic parameters 1, 2.
What the Evidence Shows
FDA Drug Label Findings
The official FDA prescribing information for dupilumab describes it as a human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling 1. The drug label does not list agglutination among its adverse effects or warnings. The mechanism of action involves inhibiting type 2 inflammatory pathways, not interfering with red blood cell structure or function 1.
Long-Term Safety Data
A comprehensive 5-year safety study of 2,677 patients treated with dupilumab found:
- No clinically meaningful changes in mean hematology parameters
- Few laboratory abnormalities reported as adverse events
- Only one case of hemolytic anemia (unrelated to agglutination) occurred in a single patient (0.02 per 100 patient-years) 2
Important Caveat: One Case Report of Evans Syndrome
There is one isolated case report from 2021 describing a 27-year-old man who developed Evans syndrome (autoimmune hemolytic anemia with thrombocytopenia) after starting dupilumab 3. However:
- This involved hemolytic anemia (red blood cell destruction), not agglutination
- The case was atypical, presenting with blurry vision and Roth spots rather than typical symptoms
- The authors speculated about a possible immunologic mechanism but established no causal relationship
- This represents a single case among thousands of patients treated with dupilumab
- The patient had a positive direct antiglobulin test (DAT), indicating antibody-mediated hemolysis, not agglutination
Clinical Distinction
Hemolytic anemia (as seen in Evans syndrome) involves antibody-mediated destruction of red blood cells, while agglutination refers to clumping of red blood cells. These are distinct phenomena with different mechanisms and clinical implications.
Bottom Line
Dupilumab does not cause red blood cell agglutination. The extensive clinical trial database, FDA labeling, and long-term safety monitoring do not support this as an adverse effect. The single case of hemolytic anemia represents a different pathologic process and remains an extremely rare, possibly coincidental finding. No routine hematologic monitoring is required during dupilumab treatment 2.